Lucid Diagnostics Q3 EPS $(0.22) Beats $(0.27) Estimate, Sales $783.00K Beat $780.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Lucid Diagnostics (NASDAQ:LUCD) reported Q3 earnings with an EPS of $(0.22), surpassing the $(0.27) estimate, and sales of $783K, slightly beating the $780K estimate. This reflects a significant improvement from the same period last year, with a 21.43% decrease in losses per share and a 930.26% increase in sales.
November 13, 2023 | 10:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lucid Diagnostics reported better-than-expected Q3 earnings and sales, indicating strong year-over-year growth and potential investor confidence.
Beating EPS and sales estimates typically generates positive investor sentiment, which can lead to a short-term increase in stock price. The substantial year-over-year growth in sales and reduction in losses per share are strong indicators of company performance and may further boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100